NexusBio Partners

Independent contractors/consultants and employees both have their place in biotech, and as a drug asset moves from bench to small animal to large animal to clinical trials the need and level of service from all types of contributors will vary by role. Using consultants/contractors allows the smaller biotechs to keep a watchful eye on expenses while moving their pipeline along at greater speed than if they had to go through a lengthy hiring process required for a high cost, long term employee. Unlike employees, when the need for services is reduced (or increased), consultants can quickly shift their work effort to align with the scientific, financial, and business needs of the customer.

Small and startup biotech companies have unique financial challenges as they balance the need to spend on science versus foundational business and accounting processes. Read why it is critical that every company, regardless of how small or how short of a time they have been in existence, has accurate, robust, and scalable business and accounting processes to support their scientific endeavors.

How do you feel about Robert F Kennedy Jr. as potential head of the HHS? Leaving political preferences aside, do you fear or welcome change to our industry? With some of the highest rates of chronic diseases in the world, do you believe there are things we can to do to make America healthy again, and that our industry should play a part, or is our current healthcare infrastructure (drugs, food, healthcare delivery, etc.) fine as it is today?

Check out our brief article on the BIOSECURE [balancing] Act...join the conversation...we would love to read your insights and thoughts! https://lnkd.in/ei8dyDb4

The BIOSECURE Act: Balancing National Security, IP Protection, and Drug Supply

Is it surprising to learn that "big pharma" contributes less to new drug development compared to "small pharma"? "Contrary to the claim that raising prices on old drugs drives innovation, large pharmaceutical companies, generally defined as those with $10 billion or more in annual sales, rarely discover new drugs," writes Gregg Girvan of FREEOPP in his analysis of data from 2013–2022 (https://lnkd.in/e_36r_MU). Emerging companies are now leading the way, bringing 52% of new drugs to market independently, compared to the 2010s, when most small companies developed a product concept only to sell it to a larger company for clinical trials and commercialization. In 2010, just 23% of emerging companies retained marketing rights to their assets. By 2022, that figure had risen to an impressive 75%. These smaller players, while spending less on R&D than their larger counterparts, are achieving better results—often with little to no revenue. This shift in the landscape is why NexusBio Partners is dedicated to supporting small and emerging biotech companies. Why? Because this is where the real innovation happens. Unlike large organizations, these smaller companies are unencumbered by bureaucracy. They are agile, adaptable, and focused—qualities we emulate at NexusBio Partners. Our mission at NexusBio Partners is to empower small and emerging biotech companies that may lack the funding or resources to advance their assets from bench to clinic to market. With our expertise, we help ensure these groundbreaking developments maintain momentum and reach the patients who need them most. We have experts that can help develop clinical strategies, design VC/funding packages that can turn science into business concepts, stand up scalable finance and operational processes/systems, and manage the science from preclinical through to clinical trials. Visit us at www.nexusbiopartners.com to learn how we can help your drug development journey succeed. #nexusbiopartners #biotech #cmc #regulatory #pharmcology #managementconsulting

NexusBio Partners is excited to announce its launch, bringing together a team of highly trusted biotech industry experts to support startup, small, and medium-sized biotech drug development companies. Recognizing the challenges these companies face in securing and funding full-time resources, NexusBio Partners offers flexible, fractional, and part-time consulting services to bridge critical expertise gaps. "We understand the unique needs of emerging biotech companies," says Dan Furlong, Managing Director of NexusBio Partners. "Our goal is to provide access to top-tier talent and strategic guidance, enabling these innovators to efficiently navigate the complex drug development landscape and accelerate their path from innovation to clinical trials." NexusBio Partners provides comprehensive support across a wide range of critical business and scientific functions, including: Research & Development: Pharmacology, Chemistry, Manufacturing, and Controls (CMC), Regulatory Affairs, Toxicology, Pathology, and Clinical Trial Design & Management Finance & Operations: Accounting, Finance, Business Operations, CRO & CDMO Vendor Management, Program Management, and Investor Relations Our experts possess decades of experience working with both small and large molecules and have a proven track record of success in organizations of all sizes. We work closely with our clients to develop tailored products and clinical strategies that drive efficient and effective development programs. Ready to take your biotech innovation to the next level? Visit our website at https://lnkd.in/eePekiqd or contact us at [email protected] to schedule an introductory call to learn more about how NexusBio Partners can help you achieve your goals. #nexusbiopartners